On the inhibition of hepatic glycogenolysis by fructose. A 31P-NMR study in perfused rat liver using the fructose analogue 2,5-anhydro-D-mannitol. 1999

K Bruynseels, and N Bergans, and N Gillis, and F van Dorpen, and P Van Hecke, and W Stalmans, and F Vanstapel
Biomedical NMR Unit, Department of Radiology, Leuven, Belgium.

Inhibition of hormone-stimulated hepatic glycogenolysis by fructose (Fru) has been attributed to accumulation of the competitive inhibitor Fru1P and/or to the associated depletion of the substrate phosphate (Pi). To evaluate the relative importance of either factor, we used the Fru analogue 2,5-anhydro-D-mannitol (aHMol). This analogue is avidly phosphorylated, traps Pi, and inhibits hormone-stimulated glycogenolysis, but it is not a gluconeogenic substrate, and hence does not confound glycogenolytic glucose production. Livers were continuously perfused with dibutyryl-cAMP (100 microM) to clamp phosphorylase in its fully activated a form. We administered aHMol (3.8 mM), and studied changes in glycogenolysis (glucose, lactate and pyruvate output) and in cytosolic Pi and phosphomonoester (PME), using in situ 31P-NMR spectroscopy (n = 4). Lobes of seven livers perfused outside the magnet were extracted for evaluation, by high-resolution 31P-NMR, of the evolution of aHMol1P and of aHMol(1,6)P2. After addition of aHMol, both glycogenolysis and the NMR Pi signal dropped precipitously, while the PME signal rose continuously and was almost entirely composed of aHMol1P. Inhibition of glycogenolysis in excess of the drop in Pi could be explained by continuing accumulation of aHMol1P. A subsequent block of mitochondrial ATP synthesis by KCN (1 mM) caused a rapid increase of Pi. Despite recovery of Pi to values exceeding control levels, glycogenolysis only recovered partially, attesting to the Pi-dependence of glycogenolysis, but also to inhibition by aHMol phosphorylation products. However, KCN resulted in conversion of the major part of aHMol1P into aHMol(1,6)P2. Residual inhibition of glycogenolysis was due to aHMol1P. Indeed, the subsequent withdrawal of aHMol caused a further gradual decrease in the proportion of aHMol1P (being converted into aHMol(1,6)P2, in the absence of de novo aHMol1P synthesis), and this resulted in a gradual de-inhibition of glycogenolysis, in the absence of marked changes in Pi. Glycogenolytic rates were consistently predicted by a model assuming non-saturated Pi kinetics and competition by aHMol1P exclusively: In conclusion, limited Pi availability and the presence of competitive inhibitors are decisive factors in the control of the in situ catalytic potential of phosphorylase a.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008353 Mannitol A diuretic and renal diagnostic aid related to sorbitol. It has little significant energy value as it is largely eliminated from the body before any metabolism can take place. It can be used to treat oliguria associated with kidney failure or other manifestations of inadequate renal function and has been used for determination of glomerular filtration rate. Mannitol is also commonly used as a research tool in cell biological studies, usually to control osmolarity. (L)-Mannitol,Osmitrol,Osmofundin
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D010758 Phosphorus A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions. Black Phosphorus,Phosphorus-31,Red Phosphorus,White Phosphorus,Yellow Phosphorus,Phosphorus 31,Phosphorus, Black,Phosphorus, Red,Phosphorus, White,Phosphorus, Yellow
D010762 Phosphorylase a The active form of GLYCOGEN PHOSPHORYLASE that is derived from the phosphorylation of PHOSPHORYLASE B. Phosphorylase a is deactivated via hydrolysis of phosphoserine by PHOSPHORYLASE PHOSPHATASE to form PHOSPHORYLASE B.
D011190 Potassium Cyanide A highly poisonous compound that is an inhibitor of many metabolic processes, but has been shown to be an especially potent inhibitor of heme enzymes and hemeproteins. It is used in many industrial processes. Potassium Cyanide (K(14)CN),Potassium Cyanide (K(C(15)N)),Cyanide, Potassium
D003600 Cytosol Intracellular fluid from the cytoplasm after removal of ORGANELLES and other insoluble cytoplasmic components. Cytosols

Related Publications

K Bruynseels, and N Bergans, and N Gillis, and F van Dorpen, and P Van Hecke, and W Stalmans, and F Vanstapel
January 1984, FEBS letters,
K Bruynseels, and N Bergans, and N Gillis, and F van Dorpen, and P Van Hecke, and W Stalmans, and F Vanstapel
January 1984, The Journal of biological chemistry,
K Bruynseels, and N Bergans, and N Gillis, and F van Dorpen, and P Van Hecke, and W Stalmans, and F Vanstapel
January 1988, The American journal of physiology,
K Bruynseels, and N Bergans, and N Gillis, and F van Dorpen, and P Van Hecke, and W Stalmans, and F Vanstapel
June 1985, Biochimica et biophysica acta,
K Bruynseels, and N Bergans, and N Gillis, and F van Dorpen, and P Van Hecke, and W Stalmans, and F Vanstapel
July 1996, The American journal of physiology,
K Bruynseels, and N Bergans, and N Gillis, and F van Dorpen, and P Van Hecke, and W Stalmans, and F Vanstapel
August 1991, The American journal of physiology,
K Bruynseels, and N Bergans, and N Gillis, and F van Dorpen, and P Van Hecke, and W Stalmans, and F Vanstapel
January 1998, Life sciences,
K Bruynseels, and N Bergans, and N Gillis, and F van Dorpen, and P Van Hecke, and W Stalmans, and F Vanstapel
July 1983, Proceedings of the National Academy of Sciences of the United States of America,
K Bruynseels, and N Bergans, and N Gillis, and F van Dorpen, and P Van Hecke, and W Stalmans, and F Vanstapel
September 2003, Biochimica et biophysica acta,
K Bruynseels, and N Bergans, and N Gillis, and F van Dorpen, and P Van Hecke, and W Stalmans, and F Vanstapel
September 2003, Biochimica et biophysica acta,
Copied contents to your clipboard!